SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-3
Document Type: S-3
Date Filed: 2025-11-26
Accession Number: 0001213900-25-115554
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000121390025115554/ea0266812-s3_synergy.htm

Chunk 23 of 26
Word Count: 1300
Character Count: 8103

Document Content:

Form S-3 we filed with the SEC under the Securities Act and does not contain all the information set forth in the registration statement. Whenever a reference is made in this prospectus supplement to any of our contracts, agreements or other documents, the reference may not be complete and you should refer to the exhibits that are a part of the registration statement or the exhibits to the reports or other documents incorporated by reference into this prospectus supplement for a copy of such contract, agreement or other document. Because we are subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended, or the Exchange Act, we file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC’s website at http://www.sec.gov. INCORPORATION OF CERTAIN INFORMATION BY REFERENCE

We are “incorporating
by reference” certain documents we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information in the documents incorporated by reference is considered to be part of this prospectus supplement.
Statements contained in documents that we file with the SEC and that are incorporated by reference in this prospectus supplement will
automatically update and supersede information contained in this prospectus supplement, including information in previously filed documents
or reports that have been incorporated by reference in this prospectus supplement, to the extent the new information differs from or is
inconsistent with the old information. We have filed or may file the following documents with the SEC and they are incorporated herein
by reference as of their respective dates of filing:

●	Annual Report on  Form 10-K  for
the year ended December 31, 2024 filed on March 31, 2025;

●	Those portions of our Definitive Proxy Statement on Schedule 14A
for our 2025 Annual Meeting of Stockholders filed with the SEC on April 28, 2025 that are incorporated by reference into our Annual
Report on Form 10-K for the year ended December 31, 2024;

●	Quarterly Reports on Form 10-Q
for the fiscal quarters ended March 31,
2025 , June 30, 2025 and September 30, 2025, respectively, filed on May 15, 2025 , August 14,
2025 , and November 13, 2025 , respectively;

●	Current Report on Form 8-K (excluding
any reports or portions thereof that are deemed to be furnished and not filed) filed on  March 31,
2025 , June 4,
2025 , June 12,
2025 , June 18,
2025 , August 27, 2025 and September 22, 2025 ; and

●	Our registration statement on  Form 8-A  filed
on October 21, 2024.

We also incorporate by reference
all documents we file under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (other than any portions of filings that are furnished
rather than filed pursuant to Items 2.02, 7.01 or 9.01 of a Current Report on Form 8-K) (a) after the initial filing date of the registration
statement of which this prospectus supplement is a part and before the effectiveness of the registration statement and (b) after the effectiveness
of the registration statement and before the filing of a post-effective amendment that indicates that the securities offered by this prospectus
supplement have been sold or that deregisters the securities covered by this prospectus supplement then remaining unsold. The most recent
information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing
will be deemed to be a part of this prospectus supplement, commencing on the date on which the document is filed.

Any statement contained in
a document incorporated or deemed to be incorporated by reference in this prospectus supplement shall be deemed modified, superseded or
replaced for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement, or in any
subsequently filed document that also is deemed to be incorporated by reference in this prospectus supplement, modifies, supersedes or
replaces such statement. Any statement so modified, superseded or replaced shall not be deemed, except as so modified, superseded or replaced,
to constitute a part of this prospectus supplement. None of the information that we disclose under Items 2.02 or 7.01 of any Current Report
on Form 8-K or any corresponding information, either furnished under Item 9.01 or included as an exhibit therein, that we may from time
to time furnish to the SEC will be incorporated by reference into, or otherwise included in, this prospectus supplement, except as otherwise
expressly set forth in the relevant document. Subject to the foregoing, all information appearing in this prospectus supplement is qualified
in its entirety by the information appearing in the documents incorporated by reference.

You may request, orally or
in writing, a copy of these documents, which will be provided to you at no cost (other than exhibits, unless such exhibits are specifically
incorporated by reference), by writing or telephoning us at the following address:

Synergy CHC Corp.

865 Spring Street

Westbrook, Maine 04092

Information about us is also
available at our website at https://www.synergychc.com. However, the information in our website is not a part of this prospectus supplement
and is not incorporated by reference.

Common Stock

PROSPECTUS SUPPLEMENT

Roth Capital Partners	Bancroft
Capital LLC

PART II

INFORMATION NOT REQUIRED IN PROSPECTUS

Item 14. Other Expenses of Issuance and Distribution

The following table sets forth
the costs and expenses payable by Synergy in connection with the sale of securities being registered. All amounts are estimates except
the SEC registration fee (which has previously been paid).

SEC Registration Fee $	13,810

FINRA Filing Fee 15,500

Legal Fees and Expenses *

Accounting Fees and Expenses *

Printing and Engraving *

Miscellaneous *

Total: $	29,310

*	Fees and expenses (other than the SEC registration fee to be paid upon the filing of this registration statement) will depend on the securities offered, the number of issuances and the nature of offerings, and cannot be estimated at this time.

Item 15. Indemnification of Directors and Officers

Neither our articles of incorporation,
nor our amended and restated bylaws, prevent us from indemnifying our officers, directors and agents to the extent permitted under the
Nevada Revised Statutes (“NRS”). NRS Section 78.7502, provides that a corporation may indemnify any director, officer,
employee or agent of a corporation against expenses, including attorneys’ fees, actually and reasonably incurred by him in connection
with any defense to the extent that a director, officer, employee or agent of a corporation has been successful on the merits or otherwise
in defense of any action, suit or proceeding referred to Section 78.7502(1) or 78.7502(2), or in defense of any claim, issue
or matter therein.

NRS 78.7502(1) provides
that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed
action, suit or proceeding, whether civil, criminal, administrative or investigative, except an action by or in the right of the corporation,
by reason of the fact that he is or was a director, officer, employee or agent of the corporation, or is or was serving at the request
of the corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise,
against expenses, including attorneys’ fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by
him in connection with the action, suit or proceeding if he: (a) is not liable pursuant to NRS 78.138; or (b) acted in good
faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect
to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful.